Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide

This publication has 36 references indexed in Scilit:

• Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model
  Molecular Therapy, 2007
• Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver
  Human Gene Therapy, 2006
• Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
  Proceedings of the National Academy of Sciences, 2006
• Malignant peripheral nerve sheath tumors with high and low Ras‐GTP are permissive for oncolytic herpes simplex virus mutants
  Pediatric Blood & Cancer, 2005
• Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical models
  Pediatric Blood & Cancer, 2004
• Oncolytic herpes simplex virus vectors for cancer virotherapy
  Cancer Gene Therapy, 2002
• Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene
  Cancer, 2002
• Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5
  Journal of Clinical Investigation, 2002
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
  New England Journal of Medicine, 1999
• An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
  Nature Biotechnology, 1998